Literature DB >> 3582462

High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer.

A E Balant-Gorgia, L Balant, T Zysset.   

Abstract

A patient showed excessive concentrations of desmethylclomipramine after receiving normal daily doses of clomipramine (Anafranil) and the elimination kinetics of the desmethylated metabolite was zero-order/saturable. Investigation showed that she was a poor metabolizer of debrisoquine and that, in addition, she had been treated with allopurinol, an inhibitor of hepatic drug metabolism.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3582462     DOI： 10.1007/bf00609967

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  6 in total

1.  Clomipramine: plasma levels and clinical effects.

Authors:  N Reisby; L F Gram; P Bech; F Sihm; O Krautwald; J Elley; J Ortmann; J Christiansen
Journal:  Commun Psychopharmacol       Date:  1979

2.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

3.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Toxicity of tricyclic antidepressants--kinetics, mechanism, intervention: a review.

Authors:  S H Preskorn; H A Irwin
Journal:  J Clin Psychiatry       Date:  1982-04       Impact factor: 4.384

5.  Plasma levels and clinical response during treatment with clomipramine.

Authors:  C Faravelli; A Ballerini; A Ambonetti; A D Broadhurst; M Das
Journal:  J Affect Disord       Date:  1984-02       Impact factor: 4.839

6.  Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.

Authors:  K Brøsen; L F Gram; R Klysner; P Bech
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
  6 in total
  5 in total

1.  Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia.

Authors:  K J Skeith; M S Hussain; R T Coutts; C Ramos-Remus; J A Avina-Zubieta; A S Russell
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

Review 2.  Clinical pharmacokinetics of clomipramine.

Authors:  A E Balant-Gorgia; M Gex-Fabry; L P Balant
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Debrisoquine oxidative phenotyping and psychiatric drug treatment.

Authors:  F Derenne; C Joanne; S Vandel; G Bertschy; R Volmat; P Bechtel
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Retrospective Review of Fluvoxamine-Clomipramine Combination Therapy in Obsessive-Compulsive Disorder in Children and Adolescents.

Authors:  Ryan Fung; Dean Elbe; S Evelyn Stewart
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2021-08-01

Review 5.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.